Antiviral therapy for chronic hepatitis B in China

详细信息    查看全文

• 作者：Xin Zheng (1)
  Junzhong Wang (1)
  Dongliang Yang (1)
  
• 关键词：Chronic hepatitis B ; Antiviral therapy ; Drug resistance ; China
• 刊名：Medical Microbiology and Immunology
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：204
• 期：1
• 页码：115-120
• 全文大小：166 KB
• 参考文献：1. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association (2011) The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi 19:13鈥?4
  2. Lok AS (2013) Hepatitis: long-term therapy of chronic hepatitis B reverses cirrhosis. Nat Rev Gastroenterol Hepatol 10:199鈥?00 CrossRef
  3. Liaw YF (2013) Reduction of cirrhosis and hepatocellular carcinoma with antiviral therapy in chronic hepatitis B. Hepatology 58:1856 CrossRef
  4. Liaw YF (2013) Impact of therapy on the outcome of chronic hepatitis B. Liver Int 33(Suppl 1):111鈥?15 CrossRef
  5. Sun J, Hou JL (2010) Management of chronic hepatitis B: experience from China. J Viral Hepat 17(Suppl 1):10鈥?7 CrossRef
  6. Karmen A, Wroblewski F, Ladue JS (1955) Transaminase activity in human blood. J Clin Invest 34:126鈥?31 CrossRef
  7. Kaplan MM (2002) Alanine aminotransferase levels: what鈥檚 normal? Ann Intern Med 137:49鈥?1 CrossRef
  8. Wang H, Xue L, Yan R, Zhou Y, Wang MS, Cheng MJ, Hai-Jun H (2013) Comparison of histologic characteristics of chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT. PLoS ONE 8:e80585 CrossRef
  9. Gui HL, Wang H, Yang YH, Wu YW, Zhou HJ, Guo SM, Lin LY et al (2010) Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase. J Viral Hepat 17(Suppl 1):44鈥?0 CrossRef
  10. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L et al (2002) Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137:1鈥?0 CrossRef
  11. Lok AS, McMahon BJ (2009) Chronic hepatitis B: update 2009. Hepatology 50:661鈥?62 CrossRef
  12. Lee JK, Shim JH, Lee HC, Lee SH, Kim KM, Lim YS, Chung YH et al (2010) Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 51:1577鈥?583 CrossRef
  13. Korean Association for the Study of the Liver (2012) KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 18:109鈥?62 CrossRef
  14. Zheng MH, Shi KQ, Fan YC, Liu WY, Lin XF, Li LF, Chen YP (2012) Upper limits of normal for serum alanine aminotransferase levels in Chinese Han population. PLoS ONE 7:e43736 CrossRef
  15. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C et al (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365:123鈥?29 CrossRef
  16. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM et al (2004) Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351:1206鈥?217 CrossRef
  17. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS et al (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354:1001鈥?010 CrossRef
  18. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH et al (2007) Entecavir therapy for up to 96聽weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133:1437鈥?444 CrossRef
  19. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G et al (2008) Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359:2442鈥?455 CrossRef
  20. European Association For The Study Of The Liver (2012) EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57:167鈥?85
  21. Dong PL, Wang DM, Zhang XM, Zhang B, Ding HG, Min J, Chen XY (2009) Efficacy and durability of generic adefovir dipivoxil in patients with HBeAg positive chronic hepatitis. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 23:473鈥?75
  22. Zhao H, Zhang YX, Chen XY, Wang L, Tang XP, Si CW (2007) A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B. Zhonghua Nei Ke Za Zhi 46:294鈥?97
  23. Wang H, Wang QH, Wang HF, Jia JD, Xie W, Qin XQ (2004) A clinical study of the efficacy and safety of secretory human interferon alpha-2a treatment for chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 12:589鈥?92
  24. Wong VW, Law MY, Hui AY, Lo AO, Li CY, Soo MT, Leung HY et al (2005) A hospital clinic-based survey on traditional Chinese medicine usage among chronic hepatitis B patients. Complement Ther Med 13:175鈥?82 CrossRef
  25. Chen Y, Zhu J (2013) Anti-HBV effect of individual traditional Chinese herbal medicine in vitro and in vivo: an analytic review. J Viral Hepat 20:445鈥?52 CrossRef
  26. He J, Zhou D, Tong G, Xing Y, Chen Y, Zhang X, Zhan B et al (2013) Efficacy and safety of a chinese herbal formula (invigorating kidney and strengthening spleen) in chronic hepatitis B virus carrier: results from a multicenter, randomized, double-blind, and placebo-controlled trial. Evid Based Complement Alternat Med 2013:961926
  27. Ma ZJ, Li Q, Wang JB, Zhao YL, Zhong YW, Bai YF, Wang RL et al (2013) Combining oxymatrine or matrine with lamivudine increased its antireplication effect against the hepatitis B virus in vitro. Evid Based Complement Alternat Med 2013:186573
  28. Guo Z, Yu S, Guan Y, Li YY, Lu YY, Zhang H, Su SB (2012) Molecular mechanisms of same TCM syndrome for different diseases and different TCM syndrome for same disease in chronic hepatitis B and liver cirrhosis. Evid Based Complement Alternat Med 2012:120350 CrossRef
  29. Wang R, Kong J, Wang D, Lien LL, Lien EJ (2007) A survey of Chinese herbal ingredients with liver protection activities. Chin Med 2:5 CrossRef
  30. Xu XH, Li GL, Qin Y, Li Q, He FQ, Li JY, Pan QR et al (2013) Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice. Virol J 10:162 CrossRef
  31. Ha M, Zhang G, Diao S, Lin M, Wu J, Sun L, She H et al (2012) Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy. Intern Med 51:1509鈥?515 CrossRef
  32. Lu JJ, Liu K, Ma YJ, Wang J, Chen EQ, Tang H (2013) Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. J Viral Hepat 20(Suppl 1):40鈥?5 CrossRef
  33. Zhang Y, Lian JQ, Li Y, Wang JP, Huang CX, Bai XF (2013) Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine. Eur J Gastroenterol Hepatol 25:814鈥?19 CrossRef
  34. Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R et al (2013) 104-week efficacy and safety of telbivudine based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology 59:1283鈥?292 CrossRef
  35. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M (2007) Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133:1445鈥?451 CrossRef
  36. Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, Brosgart CL et al (2008) Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 48:728鈥?35 CrossRef
  37. Cao Z, Zhang Y, Ma L, Sun G, He Z, Liu Y, Jin Y et al (2010) Treatment of HBeAg-positive CHB infection with peginterferon alfa-2a [40KD] (PEGASYS) plus lamivudine or adefovir for 96聽weeks results in high rates of HBsAg clearance/seroconversion. Hepatology 52(suppl 1):507A
  38. He Z, Wang J, Liu K, Huang H, Du Y, Lin Z, Cai M et al (2012) Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B. Clin Res Hepatol Gastroenterol 36:592鈥?97 CrossRef
  39. Li Y, Chen ZT, Wu JC, Gan JH, Chen JJ, Zhao WF, Luo EP (2012) Efficacy and safety of telbivudine and adefovir dipivoxil for the treatment of chronic hepatitis B patients with high level hepatitis B virus load and hepatitis B e antigen-positivity. Zhonghua Gan Zang Bing Za Zhi 20:859鈥?60
  40. Zeng W, Yuan J, Liu YX, Zhang Y, Li SX, Yao SM, Lin YM et al (2013) Efficacy of Peg-interferon alpha-2a combinated with entecavir on HBeAg positive chronic hepatitis B patients with high serum hepatitis B viral loads. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 27:115鈥?18
  41. Ma W, Zhou B, Ao F, Zhou D, Hu Y, He Q, Dai W et al (2009) Higher sustained post-treatment virologic response following peginterferon alfa-2a聽卤聽adefovir compared with adefovir monotherapy in HBeAg-positive patients. Hepatology 50(Suppl 5):494A
  
• 作者单位：Xin Zheng (1)
  Junzhong Wang (1)
  Dongliang Yang (1)
  
  1. Department of Infectious Disease, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue 1277, Wuhan, China
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Medical Microbiology
  Immunology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1831

文摘

The vaccination program against hepatitis B virus (HBV) has greatly reduced the incidence of HBV infection. However, almost one-fourth of the HBV infected patients worldwide are still located in China. The healthcare burden from chronic HBV infection is a big challenge for the Chinese government and clinicians. Antiviral therapy plays a central role in controlling chronic HBV infection and preventing the disease progression. However, due to the specific economic and medical system issues, the first-line antiviral agents recommended by the AASLD and EASL have not been widely used for Chinese patients. In this review, we will discuss some key issues in the area of antiviral treatment for chronic hepatitis B in China.